Combined chemotherapy or biotherapy with jasmonates: Targeting energy metabolism for cancer treatment

Current Pharmaceutical Biotechnology

Volumn 14, Issue 3, 2013, Pages 331-341

  Elia, Uri ^a   Flescher, Eliezer ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer; Chemotherapy; Combinational drug therapy; Jasmonate; Metabolism; Mitochondria

Indexed keywords

3 MERCAPTOPICOLINIC ACID; CASPASE 3; CD14 ANTIGEN; CD15 ANTIGEN; CISPLATIN; CYTOCHROME C; DEOXYGLUCOSE; DOXORUBICIN; HEAT SHOCK PROTEIN 72; JASMONIC ACID METHYL ESTER; NITROSOUREA; ORACIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN D2 DERIVATIVE; REACTIVE OXYGEN METABOLITE; RHODAMINE 123; STAUROSPORINE; VINCRISTINE; WORTMANNIN;

AKR1C3 GENE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BIOSYNTHESIS; BREAST CANCER; CALCIUM HOMEOSTASIS; CANCER CELL; CELL METABOLISM; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DNA FRAGMENTATION; DOWN REGULATION; ENERGY METABOLISM; FIBROSARCOMA; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GLYCOLYSIS; HUMAN; INTRACELLULAR SIGNALING; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHATIC LEUKEMIA; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL TOXICITY; MITOCHONDRION SWELLING; NECROSIS; NONHUMAN; OSTEOSARCOMA; OXIDATIVE PHOSPHORYLATION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ACETATES; ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOPENTANES; DRUG COMBINATIONS; HUMANS; MITOCHONDRIA; NEOPLASMS; OXYLIPINS;

EID: 84875357754     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201011314030008     Document Type: Article

References (85)

1. Warburg, O. The metabolism of tumors, London Constable, London, 1930.
2. Simonnet, H.; Alazard, N.; Pfeiffer, K.; Gallou, C.; Beroud, C.; Demont, J.; Bouvier, R.; Schagger, H.; Godinot, C. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis, 2002, 23, 759-768.
3. Xu, R. H.; Pelicano, H.; Zhou, Y.; Carew, J. S.; Feng, L.; Bhalla, K. N.; Keating, M. J.; Huang, P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res., 2005, 65, 613-621.
4. Maschek, G.; Savaraj, N.; Priebe, W.; Braunschweiger, P.; Hamilton, K.; Tidmarsh, G. F.; De Young, L. R.; Lampidis, T. J. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res., 2004, 64, 31-34.
5. Fanciulli, M.; Bruno, T.; Giovannelli, A.; Gentile, F. P.; Di Padova, M.; Rubiu, O.; Floridi, A. Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine. Clin. Cancer Res., 2000, 6, 1590-1597.
6. Lee, K. A.; Roth, R. A.; LaPres, J. J. Hypoxia, drug therapy and toxicity. Pharmacol. Ther., 2007, 113, 229-246.
7. Folkman, J.; Hahnfeldt, P.; Hlatky, L. Cancer: looking outside the genome. Nat. Rev. Mol. Cell Biol., 2000, 1, 76-9.
8. M. A new view of carcinogenesis and an alternative approach to cancer therapy. Mol. Med., 2010, 16, 144-153.
9. Ralph, S. J.; Rodriguez-Enriquez, S.; Neuzil, J.; Moreno-Sanchez, R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol. Aspects Med., 2010, 31, 29-59.
10. Ralph, S. J.; Rodriguez-Enriquez, S.; Neuzil, J.; Saavedra, E.; Moreno-Sanchez, R. The causes of cancer revisited: mitochondrial malignancy and ROS-induced oncogenic transformation -why mitochondria are targets for cancer therapy. Mol. Aspects Med., 2010, 31, 145-170.
11. Wang, P.; Song, J. H.; Song, D. K.; Zhang, J.; Hao, C. Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis. Cell Signal., 2006, 18, 1528-1535.
12. Cai, S.; Xu, Y.; Cooper, R. J.; Ferkowicz, M. J.; Hartwell, J. R.; Pollok, K. E.; Kelley, M. R. Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents. Cancer Res., 2005, 65, 3319-3327.
13. Tsang, W. P.; Chau, S. P.; Kong, S. K.; Fung, K. P.; Kwok, T. T. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci., 2003, 73, 2047-2058.
14. Ahn, H. J.; Kim, Y. S.; Kim, J. U.; Han, S. M.; Shin, J. W.; Yang, H. O. Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells. J. Cell Biochem., 2004, 91, 1043-1052.
15. Farber, S.; Diamond, L. K. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid. N. Engl. J. Med., 1948, 238, 787-793.
16. Goodman, L. S.; Wintrobe, M. M.; Dameshek, W.; Goodman, M. J.; Gilman, A.; McLennan, M. T. NITROGEN MUSTARD THERAPY: Use of Methyl-Bis(Beta-Chloroethyl)amine Hydrochloride and Tris(Beta-Chloroethyl)amine Hydrochloride for Hodgkin's Disease, Lymphosarcoma, Leukemia and Certain Allied and Miscellaneous Disorders. J. Am. Med. Assoc., 1946, 132, 126-132.
17. Huggins, C.; Hodges, C. V. Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. Cancer Res., 1941, 1, 293-297.
18. Hitchings, G. H.; Elion, G. B. The chemistry and biochemistry of purine analogs. Ann. N. Y. Acad. Sci., 1954, 60, 195-199.
19. Elion, G. B.; Singer, S.; Hitchings, G. H. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem., 1954, 208, 477-488.
20. Pinkel, D. Actinomycin D in childhood cancer; a preliminary report. Pediatrics, 1959, 23, 342-7.
21. Johnson, I. S.; Armstrong, J. G.; Gorman, M.; Burnett, J. P., Jr. The Vinca Alkaloids: a New Class of Oncolytic Agents. Cancer Res., 1963, 23, 1390-1427.
22. Takimoto, C.; Calvo, E. In: Cancer Management: A Multidisciplinary Approach, R.; Pazdur, L.R.; Coia, W.J.; Hoskins, L.D.; Wagman Eds. CMP Healthcare media: Manhasset, 2005, p. 23-42
23. Sembdner, G.; Parthier, B. The Biochemistry and the Physiological and Molecular Actions of Jasmonates. Ann. Rev. Plant Physiol. Plant Mol. Biol., 1993, 44, 569-589
24. Farmer, E. E.; Ryan, C. A. Interplant communication: airborne methyl jasmonate induces synthesis of proteinase inhibitors in plant leaves. Proc. Natl. Acad. Sci. USA, 1990, 87, 7713-7716.
25. Wasternack, C. Jasmonates: an update on biosynthesis, signal transduction and action in plant stress response, growth and development. Ann. Bot. (Lond), 2007, 100, 681-697.
26. Liechti, R.; Farmer, E. E. The jasmonate pathway. Science, 2002, 296, 1649-1650.
27. Mittler, R.; Lam, E. Sacrifice in the face of foes: pathogen-induced programmed cell death in plants. Trends Microbiol., 1996, 4, 10-15.
28. Dangl, J. L.; Dietrich, R. A.; Richberg, M. H. Death Don't Have No Mercy: Cell Death Programs in Plant-Microbe Interactions. Plant Cell, 1996, 8, 1793-1807.
29. Goodman, R.; Novacky, A. 1994. The Hypersensitive Response Reaction in Plants to Pathogens: A Resistance Phenomenon. American Phytopathological Society: St. Paul, MN (Abstr.).
30. Fingrut, O.; Flescher, E. Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells. Leukemia, 2002, 16, 608-616.
31. Ishii, Y.; Kiyota, H.; Sakai, S.; Honma, Y. Induction of differentiation of human myeloid leukemia cells by jasmonates, plant hormones. Leukemia, 2004, 18, 1413-1419.
32. Kim, J. H.; Lee, S. Y.; Oh, S. Y.; Han, S. I.; Park, H. G.; Yoo, M. A.; Kang, H. S. Methyl jasmonate induces apoptosis through induction of Bax/Bcl-XS and activation of caspase-3 via ROS production in A549 cells. Oncol. Rep., 2004, 12, 1233-1238.
33. Flescher, E. Jasmonates--a new family of anti-cancer agents. Anticancer Drugs, 2005, 16, 911-916.
34. Kniazhanski, T.; Jackman, A.; Heyfets, A.; Gonen, P.; Flescher, E.; Sherman, L. Methyl jasmonate induces cell death with mixed characteristics of apoptosis and necrosis in cervical cancer cells. Cancer Lett., 2008, 271, 34-46.
35. Costantini, P.; Jacotot, E.; Decaudin, D.; Kroemer, G. Mitochondrion as a novel target of anticancer chemotherapy. J. Natl. Cancer Inst., 2000, 92, 1042-1053.
36. Rotem, R.; Heyfets, A.; Fingrut, O.; Blickstein, D.; Shaklai, M.; Flescher, E. Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res., 2005, 65, 1984-1993.
37. Debatin, K. M.; Poncet, D.; Kroemer, G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene, 2002, 21, 8786-8803.
38. Newmeyer, D. D.; Ferguson-Miller, S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell, 2003, 112, 481-490.
39. Chen, L. B. Mitochondrial membrane potential in living cells. Annu. Rev. Cell Biol., 1988, 4, 155-181.
40. Dang, C. V.; Semenza, G. L. Oncogenic alterations of metabolism. Trends Biochem. Sci., 1999, 24, 68-72.
41. Davies, N. J.; Hayden, R. E.; Simpson, P. J.; Birtwistle, J.; Mayer, K.; Ride, J. P.; Bunce, C. M. AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrialmediated effects. Cancer Res., 2009, 69, 4769-4775.
42. Fingrut, O.; Reischer, D.; Rotem, R.; Goldin, N.; Altboum, I.; Zan-Bar, I.; Flescher, E. Jasmonates induce nonapoptotic death in highresistance mutant p53-expressing B-lymphoma cells. Br J Pharmacol., 2005, 146, 800-808.
43. Goldin, N.; Heyfets, A.; Reischer, D.; Flescher, E. Mitochondriamediated ATP depletion by anti-cancer agents of the jasmonate family. J. Bioenerg. Biomembr., 2007, 39, 51-57.
44. Galluzzi, L.; Kepp, O.; Tajeddine, N.; Kroemer, G. Disruption of the hexokinase-VDAC complex for tumor therapy. Oncogene., 2008, 27, 4633-4635.
45. Pedersen, P. L. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the Warburg Effect, i.e., elevated glycolysis in the presence of oxygen. J. Bioenerg. Biomembr., 2007, 39, 211-222.
46. Robey, R. B.; Hay, N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene., 2006, 25, 4683-4696.
47. Goldin, N.; Arzoine, L.; Heyfets, A.; Israelson, A.; Zaslavsky, Z.; Bravman, T.; Bronner, V.; Notcovich, A.; Shoshan-Barmatz, V.; Flescher, E. Methyl jasmonate binds to and detaches mitochondriabound hexokinase. Oncogene., 2008,
48. Tsumura, H.; Akimoto, M.; Kiyota, H.; Ishii, Y.; Ishikura, H.; Honma, Y. Gene expression profiles in differentiating leukemia cells induced by methyl jasmonate are similar to those of cytokinins and methyl jasmonate analogs induce the differentiation of human leukemia cells in primary culture. Leukemia., 2009, 23, 753-760.
49. Oh, S. Y.; Kim, J. H.; Park, M. J.; Kim, S. M.; Yoon, C. S.; Joo, Y. M.; Park, J. S.; Han, S. I.; Park, H. G.; Kang, H. S. Induction of heat shock protein 72 in C6 glioma cells by methyl jasmonate through ROS-dependent heat shock factor 1 activation. Int. J. Mol. Med., 2005, 16, 833-839.
50. Yeruva, L.; Pierre, K. J.; Carper, S. W.; Elegbede, J. A.; Toy, B. J.; Wang, R. C. Jasmonates induce apoptosis and cell cycle arrest in non-small cell lung cancer lines. Exp. Lung Res., 2006, 32, 499-516.
51. Lan, Q.; Mumford, J. L.; Shen, M.; Demarini, D. M.; Bonner, M. R.; He, X.; Yeager, M.; Welch, R.; Chanock, S.; Tian, L.; Chapman, R. S.; Zheng, T.; Keohavong, P.; Caporaso, N.; Rothman, N. Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis, 2004, 25, 2177-2181.
52. Liu, C. Y.; Hsu, Y. H.; Pan, P. C.; Wu, M. T.; Ho, C. K.; Su, L.; Xu, X.; Li, Y.; Christiani, D. C. Maternal and offspring genetic variants of AKR1C3 and the risk of childhood leukemia. Carcinogenesis, 2008, 29, 984-990.
53. Lan, Q.; Zheng, T.; Shen, M.; Zhang, Y.; Wang, S. S.; Zahm, S. H.; Holford, T. R.; Leaderer, B.; Boyle, P.; Chanock, S. Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet., 2007, 121, 161-168.
54. Cunningham, J. M.; Hebbring, S. J.; McDonnell, S. K.; Cicek, M. S.; Christensen, G. B.; Wang, L.; Jacobsen, S. J.; Cerhan, J. R.; Blute, M. L.; Schaid, D. J.; Thibodeau, S. N. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol. Biomarkers Prev., 2007, 16, 969-978.
55. Figueroa, J. D.; Malats, N.; Garcia-Closas, M.; Real, F. X.; Silverman, D.; Kogevinas, M.; Chanock, S.; Welch, R.; Dosemeci, M.; Lan, Q.; Tardon, A.; Serra, C.; Carrato, A.; Garcia-Closas, R.; Castano-Vinyals, G.; Rothman, N. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis, 2008, 29, 1955-1962.
56. Wallington, L. A.; Durham, J.; Bunce, C. M.; Drayson, M. T.; Brown, G. Triiodothyronine blocks potentiation of HL60 monocyte differentiation by anti-inflammatory agents and by steroids and induces apoptosis of all-trans retinoic acid primed cells. Leuk Res., 1997, 21, 623-634.
57. Bunce, C. M.; Mountford, J. C.; French, P. J.; Mole, D. J.; Durham, J.; Michell, R. H.; Brown, G. Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target, probably an enzyme of the aldoketoreductase family. Biochim. Biophys. Acta., 1996, 1311, 189-198.
58. Novotna, R.; Wsol, V.; Xiong, G.; Maser, E. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol. Lett., 2008, 181, 1-6.
59. Matsuura, K.; Shiraishi, H.; Hara, A.; Sato, K.; Deyashiki, Y.; Ninomiya, M.; Sakai, S. Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J. Biochem., 1998, 124, 940-946.
60. Yeruva, L.; Elegbede, J. A.; Carper, S. W. Methyl jasmonate decreases membrane fluidity and induces apoptosis through tumor necrosis factor receptor 1 in breast cancer cells. Anticancer Drugs, 2008, 19, 766-776.
61. Yeruva, L.; Pierre, K. J.; Bathina, M.; Elegbede, A.; Carper, S. W. Delayed cytotoxic effects of methyl jasmonate and cis-jasmone induced apoptosis in prostate cancer cells. Cancer Invest., 2008, 26, 890-899.
62. Tong, Q. S.; Jiang, G. S.; Zheng, L. D.; Tang, S. T.; Cai, J. B.; Liu, Y.; Zeng, F. Q.; Dong, J. H. Methyl jasmonate downregulates expression of proliferating cell nuclear antigen and induces apoptosis in human neuroblastoma cell lines. Anticancer Drugs, 2008, 19, 573-581.
63. Tong, Q. S.; Jiang, G. S.; Zheng, L. D.; Tang, S. T.; Cai, J. B.; Liu, Y.; Zeng, F. Q.; Dong, J. H. Natural jasmonates of different structures suppress the growth of human neuroblastoma cell line SH-SY5Y and its mechanisms. Acta. Pharmacol. Sin., 2008, 29, 861-869.
64. Samaila, D.; Ezekwudo, D. E.; Yimam, K. K.; Elegbede, J. A. Bioactive plant compounds inhibited the proliferation and induced apoptosis in human cancer cell lines, in vitro. TIBETS, 2004, 1, 34-42.
65. Frei, E.; Antman, K. H. In: Cancer Medicine, R.C Bast Jr., D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, J.F. Holland, E. Frei, T.S. Gansler E.ds.; B.C. Decker: Hamilton 2003; p. 817-837
66. Reynolds, C. P.; Maurer, B. J. Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol. Med., 2005, 110, 173-183.
67. Lampidis, T. J.; Bernal, S. D.; Summerhayes, I. C.; Chen, L. B. Selective toxicity of rhodamine 123 in carcinoma cells in vitro. Cancer Res., 1983, 43, 716-720.
68. Fearon, K. C.; Plumb, J. A.; Burns, H. J.; Calman, K. C. Reduction of the growth rate of the Walker 256 tumor in rats by rhodamine 6G together with hypoglycemia. Cancer Res., 1987, 47, 3684-3687.
69. Heyfets, A.; Flescher, E. Cooperative cytotoxicity of methyl jasmonate with anti-cancer drugs and 2-deoxy-D-glucose. Cancer Lett., 2007, 250, 300-310.
70. Elia, U.; Flescher, E. PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells. Neoplasia., 2008, 10, 1303-1313.
71. Yeruva, L.; Hall, C.; Elegbede, J. A.; Carper, S. W. Perillyl alcohol and methyl jasmonate sensitize cancer cells to cisplatin. Anticancer Drugs, 2010, 21, 1-9.
72. Osaki, M.; Oshimura, M.; Ito, H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis, 2004, 9, 667-676.
73. Sroka, I. C.; Nagle, R. B.; Bowden, G. T. Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. Neoplasia., 2007, 9, 406-417.
74. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2002, 2, 489-501.
75. West, K. A.; Castillo, S. S.; Dennis, P. A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat., 2002, 5, 234-248.
76. Mookherjee, P.; Quintanilla, R.; Roh, M. S.; Zmijewska, A. A.; Jope, R. S.; Johnson, G. V. Mitochondrial-targeted active Akt protects SH-SY5Y neuroblastoma cells from staurosporine-induced apoptotic cell death. J. Cell Biochem., 2007, 102, 196-210.
77. Nesterov, A.; Lu, X.; Johnson, M.; Miller, G. J.; Ivashchenko, Y.; Kraft, A. S. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem., 2001, 276, 10767-10774.
78. VanderWeele, D. J.; Zhou, R.; Rudin, C. M. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol. Cancer Ther., 2004, 3, 1605-1613.
79. Perez-Tenorio, G.; Stal, O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer, 2002, 86, 540-545.
80. Murakami, D.; Tsujitani, S.; Osaki, T.; Saito, H.; Katano, K.; Tatebe, S.; Ikeguchi, M. Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy. Gastric. Cancer, 2007, 10, 45-51.
81. Tomita, Y.; Morooka, T.; Hoshida, Y.; Zhang, B.; Qiu, Y.; Nakamichi, I.; Hamada, K.; Ueda, T.; Naka, N.; Kudawara, I.; Aozasa, K. Prognostic significance of activated AKT expression in softtissue sarcoma. Clin. Cancer Res., 2006, 12, 3070-3077.
82. Gottlob, K.; Majewski, N.; Kennedy, S.; Kandel, E.; Robey, R. B.; Hay, N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes. Dev., 2001, 15, 1406-1418.
83. Majewski, N.; Nogueira, V.; Bhaskar, P.; Coy, P. E.; Skeen, J. E.; Gottlob, K.; Chandel, N. S.; Thompson, C. B.; Robey, R. B.; Hay, N. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell, 2004, 16, 819-830.
84. Majewski, N.; Nogueira, V.; Robey, R. B.; Hay, N. Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol. Cell Biol., 2004, 24, 730-740.
85. Ezekwudo, D.; Shashidharamurthy, R.; Devineni, D.; Bozeman, E.; Palaniappan, R.; Selvaraj, P. Inhibition of expression of antiapoptotic protein Bcl-2 and induction of cell death in radioresistant human prostate adenocarcinoma cell line (PC-3) by methyl jasmonate. Cancer Lett., 2008, 270, 277-285.